Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
|Title:||Antiarhythmic pharmaceutical preparation containing ethyl 10-.alpha.-morpholylpropionyl) phenthiazine-2-carbamate hydrochloride|
|Abstract:||A method for preparing a novel composition of matter, ethyl 10-(.beta.-morpholylpropionyl)-phenthiazine-2-carbamate hydrochloride, having the formula ##SPC1## Which comprises reacting ethyl phenthiazine-2-carbamate with .beta.-chloropropionyl chloride in an inert organic solvent at the boiling point of the solvent used, condensing the resulting ethyl 10-(.beta.-chloropropionyl)-phenthiazine-2-carbamate with morpholine in an inert organic solvent, treating the ethyl 10-(.beta.-morpholylpropionyl)-phenthiazine-2-carbamate with hydrogen chloride, and separating the desired compound. The novel compound, ethyl 10-(.beta.-morpholylpropionyl)-phenthiazine-2-carbamate hydrochloride, is the active principle of an antiarhythmic pharmaceutical preparation.|
|Inventor(s):||Gritsenko; Anna Nikitichna (Moscow, SU), Vikhlyaev; Jury Ivanovich (Moscow, SU), Zhuravlev; Semen Vladimirovich (Moscow, SU), Kaverina; Natalya Veniaminovna (Moscow, SU), Senova; Zlata Petrovna (Moscow, SU), Ulyanova; Olga Vasilievna (Moscow, SU)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Dosage form; Formulation;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.